Roche 'steps up' for gene therapy with $4.3 billion Spark bet

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to "step up", Chief Executive Severin Schwan said on Monday.